Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

An observational study of cardiovascular patients in India

ABSTRACT: Serum samples for CVD patients were analyzed by untargeted metabolomics assays to identify prognostic biomarkers.

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Heart Disease

SUBMITTER: Yashwant Kumar

PROVIDER: ST002044 | MetabolomicsWorkbench | Wed Dec 22 00:00:00 GMT 2021

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Targeted next generation sequencing of cfDNA from lung cancer patients enrolled in the GALAXY-1 trial (NCT01348126)

Project description:We evaluated whether targeted next-generation sequencing (NGS) using the Ion Torrent Personal Genome Sequencer of cfDNA could identify prognostic or predictive factors for overall survival (OS) or progression free survival (PFS) within a large cohort of patients with advanced lung adenocarcinoma enrolled in the GALAXY-1 trial.

2018-01-10 | E-MTAB-5749 | biostudies-arrayexpress

Biomarkers in older ovarian cancer patients

Project description:Identification and validation of potential prognostic biomarkers in older ovarian cancer patients with high-grade serous adenocarcinoma (HGSC)

2020-03-01 | GSE126308 | GEO

Expression data from early stage CRC patients' tumors [Agilent]

Project description:This study was conducted in order to identify biomarkers for a prognostic gene expression signature for metastases in early stage CRC.

2017-08-02 | GSE81981 | GEO

Expression data from early stage CRC patients' tumors [Affymetrix]

Project description:This study was conducted in order to identify biomarkers for a prognostic gene expression signature for metastases in early stage CRC.

2017-08-02 | GSE81980 | GEO

Expression data from early stage CRC patients' tumors [NanoString-Test]

Project description:This study was conducted in order to identify biomarkers for a prognostic gene expression signature for metastases in early stage CRC.

2017-08-02 | GSE81985 | GEO

Expression data from early stage CRC patients' tumors [NanoString-Design]

Project description:This study was conducted in order to identify biomarkers for a prognostic gene expression signature for metastases in early stage CRC.

2017-08-02 | GSE81983 | GEO

Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival of colorectal cancer Stage III patients

Project description:Surgical resection is the major clinical intervention for Stage III colorectal cancer (CRC) currently. However, as much as 30.8% of the patients who had ever taken curative resection came out of recurrence eventually. Therefore, to facilitate formulating effective treatment plans, there is an intense demand for Stage III CRC post-surgical prognostic biomarkers. In this study, we identified total 146 differentially expressed proteins (DEPs) associated with poor prognosis in Stage III CRC patients with TMT-based quantitative mass spectrometry (MS). In these DEPs, the protein expression level of R-Ras and Transgelin were tested with immunohistochemistry (IHC) of 192 individual specimens. Further Kaplan-Meier analysis revealed that the level of R-Ras and Transgelin is associated with patients’ 5-year overall survival (OS) and disease-free survival (DFS) significantly, and multivariate Cox-regression analyses revealed that R-Ras and Transgelin are independent prognostic factors for OS and DFS respectively. In conclusion, our study presents that R-Ras and Transgelin are potential post-surgical prognostic biomarkers of Stage III CRC.

2016-06-20 | PXD002903 | Pride

Study on prognostic biomarkers of HCC based on mass spectrometry

Project description:using DIA, and PRM MS-based workflow to research the prognostic biomarkers of HCC

2022-02-17 | PXD027817 | Pride

Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients

Project description:Information on the immunopathobiology of coronavirus disease 2019 (COVID-19) is rapidly increasing; however, there remains a need to identify immune features predictive of fatal outcome. This large-scale study characterized immune responses to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection using multidimensional flow cytometry, with the aim of identifying high-risk immune biomarkers. Holistic and unbiased analyses of 17 immune cell-types were conducted on 1,075 peripheral blood samples obtained from 868 COVID-19 patients and on samples from 24 patients presenting with non-SARS-CoV-2 infections and 36 healthy donors. Immune profiles of COVID-19 patients were significantly different from those of age-matched healthy donors but generally similar to those of patients with non-SARS-CoV-2 infections. Unsupervised clustering analysis revealed three immunotypes during SARS-CoV-2 infection; immunotype 1 (14% of patients) was characterized by significantly lower percentages of all immune cell-types except neutrophils and circulating plasma cells, and was significantly associated with severe disease. Reduced B-cell percentage was most strongly associated with risk of death. On multivariate analysis incorporating age and comorbidities, B-cell and non-classical monocyte percentages were independent prognostic factors for survival in training (n=513) and validation (n=355) cohorts. Therefore, reduced percentages of B-cells and non-classical monocytes are high-risk immune biomarkers for risk-stratification of COVID-19 patients.

2021-05-03 | GSE155897 | GEO

Expression data of diagnostic biopsy samples from Hodgkin lymphoma patients

Project description:Despite advances in Hodgkin lymphoma (HL) treatment, about 20% of patients still die due to progressive disease. Current prognostic models predict treatment outcome with imperfect accuracy, and clinically relevant biomarkers are yet to be established that improve upon the International Prognostic Scoring (IPS) system. We analyzed 130 frozen diagnostic lymph node biopsies from classical HL patients by gene expression profiling to describe cellular signatures correlated with treatment outcome.

2010-03-01 | GSE17920 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data